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Abstract Since the advent of tyrosine kinase inhibitors, the
impact of age on outcome of chronic myeloid leukemia
(CML) patients has changed. We therefore analyzed patients
from the randomized CML study IV to investigate disease
manifestations and outcome in different age groups. One
thousand five hundred twenty-four patients with BCR-ABL-
positive chronic phase CML were divided into four age
groups: (1) 16–29 years, n =120; (2) 30–44 years, n =383;
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(3) 45–59 years, n =495; and (4)≥60 years, n =526. Group 1
(adolescents and young adults (AYAs)) presented with more
aggressive disease features (larger spleen size, more frequent
symptoms of organomegaly, higher white blood count, higher
percentage of peripheral blasts and lower hemoglobin levels)
than the other age groups. In addition, a higher rate of patients
with BCR-ABL transcript levels >10 % on the international
scale (IS) at 3 months was observed. After a median
observation time of 67.5 months, no inferior survival and no
differences in cytogenetic and molecular remissions or
progression rates were observed. We conclude that AYAs
show more aggressive features and poor prognostic indicators
possibly indicating differences in disease biology. This,
however, does not affect outcome.
Keywords Chronic myeloid leukemia . Accelerated phase .
Blast crisis . Young adults and adolescents
Introduction
Chronic myeloid leukemia (CML) appears in all age groups.
The incidence increases with age. In western countries,
median age at diagnosis is 64 years [1, 2] and around 54 years
[3] in clinical studies. Before the introduction of imatinib,
older age was a negative prognostic factor, as reflected by
the risk stratification scores, Sokal and Euro [4, 5]. After the
introduction of imatinib, the outcome of patients with CML
has improved, and older age seems to have lost its negative
impact [6, 7].
A recent analysis that compares patients less than 65 years
with patients older than 65 years treated with frontline
imatinib reports no difference in an outcome between these
two age groups [8]. Another analysis that compares 15–29-
year-old adolescents and young adults (AYAs) with patients
older than 29 years with newly diagnosed chronic phase (CP)
CML treated with first-line tyrosine kinase inhibitors (TKIs)
reports inferior response rates in the younger group [9]. AYAs
have been of particular interest in oncology because
differences compared to older age have been observed in
various neoplasias: In acute lymphoblastic leukemia, different
disease features and a better outcome are reported in AYAs in
comparison to older patients [10, 11]. A worse prognosis has
been reported in breast cancer [12, 13], colorectal cancer [14],
and soft tissue sarcomas [15], pointing to different biological
features of these cancers in younger age [16].
Few data exist on presentation and outcome of AYAs with
CML possibly due to the low incidence of CML in this age
group.
The aim of this study was to analyze the impact of age on
outcome of CML using patients from the German CML study
IV with particular attention to the group of patients younger
than 29 years.
Patients and methods
The German CML study IV is a five-arm randomized study
which compares 400 mg imatinib, 800 mg imatinib, 400 mg
imatinib in combination with interferon alpha (IFN-α),
400 mg imatinib in combination with low-dose cytarabine,
and 400 mg imatinib after failure to IFN-α [17].
Newly diagnosed BCR-ABL-positive CP-CML patients
diagnosed in participating centers were included. There was
no upper age limit. Patients with comorbidities that would
preclude study participation or study drug treatment were
excluded as well as pregnant or nursing women and patients
with secondary malignancy causing reduced life expectancy
or requiring therapy.
Patients, 16 years and older, were included. Twenty-nine
years was defined as upper cutoff age for AYAs [9, 18–21].
For older patients, the lower cut off at age 60 years was chosen
[6, 22]. Age groups, 30–59, were evenly divided into two
groups (30–44 and 45–59).
Gender, performance status, risk scores, clinical
manifestations, blood count, type of transcripts, and presence
of additional chromosomal aberrations (ACAs) [23] were
analyzed at the time of diagnosis. Cytogenetic and molecular
responses, rates of progression to accelerated phase (AP) and
blast crisis (BC), and overall survival (OS) were analyzed
throughout the observation time of the study. Patients were
analyzed for achieving complete cytogenetic remission
(CCR), major molecular remission (MMR), and molecular
K. Spiekermann
Medizinische Klinik und Poliklinik III, Klinikum der Ludwig
Maximilians-Universität, Munich, Germany
S. W. Krause
Medizinische Klinik 5, Universitätsklinikum Erlangen, Erlangen,
Germany
D. Heim
Klinik für Hämatologie, Universitätsspital, Basel, Switzerland
C. Nerl
Klinik für Hämatologie, Onkologie, Immunologie, Palliativmedizin,
Infektiologie und Tropenmedizin, Klinik Schwabing, Munich,
Germany
D. K. Hossfeld
II. Medizinische Klinik, Universitätsklinikum Eppendorf, Hamburg,
Germany
H.<J. Kolb
Klinikum rechts der Isar, Technische Universität München, Munich,
Germany
A. Hochhaus
Abteilung Hämatologie/Onkologie, Universitätsklinikum Jena, Jena,
Germany
72 Ann Hematol (2014) 93:71–80
remission ≤0.01 % on the international scale (MR4), if at least
one sample of sufficient quality was available.
For follow-up analyses of CCR, at least 20 marrow cell
metaphases were evaluated. Measurements of BCR-ABL and
total ABL transcripts were determined by quantitative reverse
transcriptase polymerase chain reactions from peripheral
blood samples [24–26] and were performed in standardized
laboratories [27]. The analysis of molecular endpoints was
restricted to patients expressing b2a2 and/or b3a2 transcripts
only.
Response definitions, AP, and BC were defined according
to ELN criteria and the recent standardized definitions of
molecular response [28–30]. All living patients were censored
at the time of their last visit. In estimating the cumulative
incidences of molecular or cytogenetic remissions, patients
were censored at the time they received a second-generation
TKI or were transplanted.
OSwas calculated from date of diagnosis to death from any
cause (whether on or off TKI) or to the latest follow-up date.
Baseline characteristics and hematological parameters were
compared with the chi-squared or the Kruskal–Wallis tests.
Cumulative incidences were calculated under consideration
of competing risks [31, 32] defined by AP, BC, and death.
Probabilities of OS were calculated by the Kaplan–Meier
method and compared by log-rank test. Comparisons between
cumulative incidences were performed by the Gray test [33].
Relative overall survival was calculated dividing the observed
survival probabilities by the expected survival probability of
the general German population matching age and sex. Level of
significance was 0.05. Due to the exploratory character of this
work, no adjustment of p values was done. All calculations
were performed with the SAS software Version 9.1.3.
The protocol followed the Declaration of Helsinki and was
approved by the ethics committee of the Medizinische
Evaluable for OS 
n = 1524
Excluded: n = 13
no CML, not in CP, no informed consent  
Randomized by 31.3.2012 
n = 1551
In study: n = 1538
Withdrawal of consent: n = 2 
Missing baseline data: n = 12
16 – 29 years
n = 120
CCR n = 109
MMR n = 114
MR4 n = 104
30 – 44 years
n = 383




CCR n = 365
MMR n = 358
MR4 n = 330
CCR n = 469
MMR n = 461
MR4 n = 446
CCR n = 498
MMR n = 475
MR4 n = 446
Fig. 1 Overview of evaluable
patients according to age groups.
n Number of patients, CML
chronic myeloid leukemia, CP
chronic phase, OS overall
survival, CCR complete
cytogenetic remission, MMR
major molecular remission, MR4
molecular remission ≤0.01 % on
the international scale
Table 1 Patients and treatment
arms
N number of patients, IFN-α
interferon
Age groups, years 16–29 30–44 45–59 At least 60
All patients, n 120 383 495 526
Imatinib (400 mg), n (%) 25 (21) 93 (24) 131 (26) 147 (28)
Imatinib (400 mg + IFN-α), n (%) 39 (32) 102 (27) 139 (28) 145 (27)
Imatinib (400 mg + cytarabine), n (%) 13 (11) 39 (10) 53 (11) 53 (10)
Imatinib (400 mg after IFN-α failure), n (%) 8 (7) 35 (9) 37 (7) 48 (9)
Imatinib (800 mg), n (%) 35 (29) 114 (29) 135 (27) 133 (25)
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Table 2 Patient's characteristics
Age groups, years 16–29 30–44 45–59 At least 60
Number of patients, n (%) 120 (8) 383 (25) 495 (32) 526 (35)
Male 80 (67) 255 (67) 301 (61) 283 (54)
Female 40 (33) 128 (33) 194 (39) 243 (46)
p 0.011a
Karnofsky index, n (%)
50–80 13 (12) 31 (9) 42 (9) 74 (16)
>80–<100 32 (29) 86 (25) 144 (32) 166 (35)
100 65 (59) 226 (66) 271 (59) 234 (49)
p <0.001a <0.001a <0.001a
Missing 10 40 38 52
EUTOS score, n (%)
Low 97 (82) 320 (84) 436 (89) 473 (92)
High 22 (18) 63 (16) 54 (11) 41 (8)
p 0.031a 0.002a
Missing 1 0 5 12
Sokal score b, n (%)
Low 64 (54) 190 (50) 226 (46) 90 (17)
Intermediate 23 (19) 100 (26) 155 (32) 300 (58)
High 31 (26) 92 (24) 110 (22) 125 (24)
p 0.035a <0.001a
Missing 2 1 4 11
Euro score b, n (%)
Low 70 (59) 267 (70) 144 (29) 69 (13)
Intermediate 29 (24) 84 (22) 286 (58) 391 (75)
High 20 (17) 31 (8) 65 (13) 61 (12)
p 0.013a <0.001a <0.001a
Missing 1 1 0 5
Presence of organomegaly-related symptoms, n (%) 33 (29) 86 (24) 84 (18) 37 (7)
p 0.009a <0.001a
Missing 5 19 18 23
Spleen size, below costal margin
Median (range), cm 5 (0–38) 3 (0–28) 1 (0–25) 0 (0–23)
p 0.014a <0.001a <0.001a
Missing, n 1 0 2 6
Blasts in blood
Median (range), % 2 (0–19)c 1 (0–17)c 1 (0–30)c 0 (0–15)
p 0.010a <0.001a
Missing, n 1 1 4 6
WBC
Median (range), 109/L 144 (9–571) 106 (3–539) 74 (3–630) 57 (3–582)
p 0.044a <0.001a <0.001a
Missing, n 1 2 2 3
Hemoglobin
Median (range), g/dL 11.1 (6.9–16.2) 11.8 (5.2–17.5) 12.6 (4.9–19.1) 12.5 (4.7–17.6)
p 0.041a <0.001a <0.001a
Missing, n 2 3 3 5
Eosinophils
Median (range), (%) 2.5 (0–12) 2 (0–13) 2 (0–14) 2 (0–28)
Missing, n 0 2 4 3
74 Ann Hematol (2014) 93:71–80
Fakultät Mannheim der Universität Heidelberg and by local
ethics committees of participating centers. Written informed
consent was obtained from all patients before they entered the
study.
Results
One thousand five hundred fifty-one patients with newly
diagnosed BCR-ABL-positive CML in CP were randomized
from July 2002 through March 2012. Data entry was closed
on May 24, 2012.
One thousand five hundred twenty-four patients at the age
of 16 years and older were evaluable for follow-up (Fig. 1).
The median age at diagnosis was 52 years. The median
observation time was 67.5 (0.1–123.8)months.
Patients were divided into four age groups according to age
at diagnosis: group 1, 16–29 years (n =120, 8 %); group 2,
30–44 years (n =383, 25 %); group 3, 45–59 years (n =495,
32 %); and group 4, ≥60 years (n =526, 35 %). All patients
received imatinib as first or second-line treatment in the
study except for ten patients who only received IFN.
Recruitment to this arm was terminated in 2005 [17].
More patients in group 1 were transplanted (19 %) compared
to 12, 7, and 1 % in groups 2, 3, and 4, respectively. The
number of patients according to age groups and therapy arm
are shown in Table 1.
There was a predominance of male gender in all age
groups, but group 1 showed a significantly higher percentage
of male patients in comparison to group 4 (67 % for groups 1
and 2 each, 61% for group 3, and 54% for group 4, p =0.011).
Most patients had a Karnofsky index >80 %, but 12 % of
patients in group 1 had a Karnofsky index between 50–80 %
compared to 9 % in groups 2 and 3 and 16 % in group 4
(Table 2).
Patients in group 1 had the highest proportion of high-risk
patients according to Euro and EUTOS scores. By EUTOS
score, 18 % of patients in group 1 were high risk in
comparison to 16 % (ns), 11 % (p =0.031), and 8 % (p <
0.002) in groups 2, 3, and 4, respectively.
Table 2 (continued)
Age groups, years 16–29 30–44 45–59 At least 60
Basophils
Median (range), (%) 3 (0–19) 3 (0–22) 4 (0–26) 3 (0–66)
Missing, n 0 2 5 6
Platelets
Median (range), × 109/L 430 (59–2,590) 369 (39–2,799) 364 (49–3,020) 381 (34–2,716)
Missing, n 0 1 1 2
BCR-ABL transcript type, n (%)
b2a2 55 (48) 146 (39) 200 (42) 186 (38)
b3a2 42 (36) 166 (45) 210 (44) 233 (47)
Either 18 (16) 61 (16) 65 (14) 72 (15)
Missing 5 10 20 35
ACAs, n (%)
Yes 6 (6) 13( 4) 22(5) 12(3)
No 98 (94) 321 (96) 421 (95) 452 (97)
Missing 16 49 52 62
>10 % BCR-ABL IS at 3 months
n , (%) 25(42) 74(42) 60 (26) 53 (25)
p 0.026a 0.018a
Missing, n 60 204 263 313
>10 % BCR-ABL IS at 6 months
n , (%) 6 (13) 30(19) 28(13) 29(15)
Missing, n 72 224 272 320
BCR-ABL IS BCR-ABL transcript levels on international scale ACAs: additional cytogenetic aberrations except −Y
a p value refers to test between group 1 and the respective groups. Values not shown were above 0.05
b In Sokal and Euro score age is included for risk stratification
c Eight patients with blasts in blood > 15%were included as chronic phase patients after judged so by the treating physicians. All had bonemarrow blasts
≤10 %
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Group 1 presented with a larger spleen size (median length
of 5 cm below the costal margin), more often with symptoms
of organomegaly, higher white blood cell counts (WBC), a
higher percentage of blasts in the peripheral blood (median of
144×109/L), and lower hemoglobin levels (median of 11.1
g/dL). There were no differences in fatigue, weight loss, fever,
or other symptoms, in the percentage of eosinophils,
basophils, platelets, bone marrow blasts, ACAs, and type of
BCR-ABL transcripts at diagnosis between the four groups
(Table 2).
No significant differences in cumulative incidences of
CCR, MMR, and MR4 were found between group 1 and the
other 3 groups (Fig. 2a–c).
The 5-year OS probability of group 1 was 96.7 %,
93.8 % for group 2, 92.5 % for group 3, and 82.9 %
for group 4. OS was lower only in group 4 in
comparison to the other three age groups (p <0.001) as
observed in the general population [34]. The relative
survival (RS) when the general German population
was taken into account was 96.9 % in group 1, 94.5,
95.1, and 93.1 % in groups 2–4, respectively [34].
Regarding progression during the observation time, no
differences were observed between the age groups. The
cumulative incidences of progression at 5 years were 8.7,
7.3, 5.3, and 6.1 % for groups 1 to 4, respectively (Fig. 3).
More patients in group 1 had BCR-ABL IS ≥10 % at
3 months (42 %) than patients above 44 years (26 % for group
3, p =0.026 and 25 % for group 4, p =0.018). There was no
difference to group 2 (Table 2).
A correlation between a specific cause of death age group
and therapy arm was not observed. Causes of death in each
group are shown in Table 3.
Discussion
The median age of the 1,524 CML patients of the CML study
IV was 52 years with a male preponderance. AYAs
represented 8 % of the study population in agreement with
reports of CML incidence in AYAs [9, 35].
AYAs in our study presented features of a more aggressive
disease, with higher levels ofWBC and blasts in the peripheral
blood, lower hemoglobin, larger spleen size, and more
frequent organomegaly-related symptoms. The larger spleen
size is reflected in the EUTOS score in which age is not
included as a parameter and is in line with a study of
Pemmaraju et al. who report a higher frequency of
splenomegaly at diagnosis in 61 AYAs than in 407 older
patients [9], and a study of Cortes et al. who report that
splenomegaly was more frequent in patients below 60 years
than above 60 years [6]. Similar observations have been made
in children with CML (increased rates of splenomegaly and
leucocytosis) [36–38], supporting our findings that aggressive
disease features become less apparent as age increases.
Age, years n Median, months
16 – 29 109 13.1
30– 44 365 13.0
























Age, years n Median, months
16 – 29 114 17.6
30– 44 358 17.4












































Age, years n Median, months
16 – 29 104 39.0
30– 44 330 36.8






Fig. 2 a–c Cumulative incidences of a CCR, b MMR, and c MR4
according to the four age groups determined under consideration of
competing risks. n Number of patients, CCR complete cytogenetic,
remission, MMR major molecular remission, MR4 molecular remission
≤0.01 % on the international scale. p refers to level of significance
between AYAs and the other three age groups
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Although a worse outcome was expected in our group of
120AYAs [9], no differences in cumulative incidence of CCR,
MMR, and MR4 were observed in comparison to the other
three groups. This is different from the results of Pemmaraju
et al. [9] who report significantly lower cytogenetic and
molecular responses in AYAs. The two studies however did
not find difference in OS. No inferior survival after a median
observation time of 5.6 years was observed in our study either.
We have observed, however, a greater percentage of younger
patients with BCR-ABL transcript levels above 10 % at
3 months in comparison to patients 44 years and older.
Transcript levels above 10 % are correlated with an
unfavorable prognosis [39, 40] and identify patients that
require more frequent monitoring [41].
These findings could suggest different disease biology of
CML in younger patients. The identification of distinct age-
related genetic and biologic features has been found in various
neoplasms: in colon cancer chromosomal instability and a
greater tumor invasion is observed in younger patients [42].
In papillary thyroid cancer, different gene expression and
advanced disease presentation in AYAs were correlated with
better prognosis [43]. In breast cancer, younger women show
unique genetic pathways recognized as negative prognostic
markers [13]. In acute lymphoblastic leukemia (ALL), distinct
Patients at risk 1 2 3 4 5 6 7 8 9
16 – 29 years 110 99 89 75 60 42 18 11 3
30 – 44 years 354 326 277 240 193 151 91 55 16
45 – 59 years 475 442 376 321 269 200 145 80 33
60 years 490 430 384 315 252 187 136 78 37
Age, years n AP / BC, n 5 year CI, %
16 – 29 120 11 8.7
30– 44 383 28 7.3
45– 59 495 25 5.3



















Fig. 3 Rates of progression to
AP and BC according to age
group. No statistical difference
was observed between the four
age groups. n Number of patients,
AP accelerated phase, BC blast
crisis, CI cumulative incidence.
p refers to level of significance
between AYAs and the other three
age groups
Table 3 Causes of death
Multiple causes are possible.
Autopsy performed only in few
cases
n number of patients, AP
accelerated phase, BC blast crisis,
CP chronic phase, SCT stem cell
transplantation
Age groups, years 16–29 30–44 45–59 At least 60
All patients, n 120 383 495 526
Total deaths 4 23 38 87
Progression to AP, BC 1 7 13 22
SCT related 2 6 8 1
Infection in CP 0 2 2 8
Secondary malignancy 0 0 2 21
Bleeding 0 2 1 0
Cardiopulmonary 1 0 2 14
Renal insufficiency 0 0 0 3
Thromboembolic/ischemic (not cardiac) 0 1 2 2
Suicide 0 0 0 2
Others 0 1 2 4
Unknown 0 4 6 10
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biological findings are reported in AYAs, which are generally
correlated with poor prognosis: increased incidence of
Philadelphia chromosome and intrachromosomal
amplification of chromosome 21, increased promoter
methylation, and more frequent T cell immunophenotype as
well as presence of a mediastinal mass. Due to treatment
optimization, ALL outcome is better in AYAs than in adults
[10, 11, 44].
In our analysis, we did not detect obvious biological
differences. We did not observe differences in transcript type
or ACAs nor did others: no differences in transcript type in
relation to age were found in 146 pediatric CML patients,
including 30 AYAs [36]. Differences in stem cell biology,
bone marrow microenvironment, or signaling pathways could
exist since many biologic pathways are triggered by BCR-
ABL and are successfully inhibited by TKI therapy [45–47]
but data to support this in AYAs are still lacking.
Another possible interpretation of the more aggressive
features at diagnosis of CML in AYAs could be that younger
patients are less frequently transferred to the physician than
older ones and only when symptoms are apparent as a
consequence of better health and less frequent comorbidities
than in older people. As there are no data to support this
hypothesis, this remains speculative.
Since the introduction of imatinib, response rates have
improved and progression of the disease rarely occurs [48].
Treatment with imatinib explains the high 5-year OS of AYAs
in our study (97 %) in comparison to a recently published
population-based study in the Netherlands, which started in
the pre-imatinib era (1989–2009), in which the 5-year relative
survival of AYAs with CML is reported to be 68 % in males
and 76 % in females [49].
We conclude that AYAs with CML show features of a more
aggressive disease indicating possible biological differences
of younger patients that need to be investigated. Also, the
higher transcript level at 3 months suggests a worse prognosis
of AYAs. Nevertheless, younger patients do well in spite of
poorer prognostic indicators.
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